H.C. Wainwright lowered the firm’s price target on Summit Therapeutics (SMMT) to $23 from $30 and keeps a Buy rating on the shares. The firm says the absence of a stronger interim signal in HARMONi-3 suggests the final squamous readout in the second half of 2026 now carries more risk.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Summit Therapeutics Flags Significant Going-Concern Risk Amid Cash Shortfall and Uncertain Financing
- Midday Fly By: Apple reports Q2 beat, oil majors post mixed results
- Summit Therapeutics falls -23.7%
- Summit Therapeutics falls -27.4%
- Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler